MaxCyte, Inc. Reports Leadership Changes and Compensation Details
Ticker: MXCT · Form: 8-K · Filed: Aug 11, 2025 · CIK: 1287098
Sentiment: neutral
Topics: leadership-change, officer-appointment, compensation
Related Tickers: MXCT
TL;DR
MaxCyte leadership shuffle: new officers appointed, exec pay adjusted.
AI Summary
MaxCyte, Inc. filed an 8-K on August 11, 2025, reporting on the departure of directors or certain officers, the election of directors, and the appointment of certain officers, as well as compensatory arrangements for certain officers. The filing details changes within the company's leadership and executive compensation structure.
Why It Matters
This filing indicates potential shifts in the company's strategic direction or operational focus due to changes in key personnel and their compensation.
Risk Assessment
Risk Level: medium — Changes in executive leadership and compensation can signal internal shifts that may impact future performance and strategy.
Key Numbers
- 001-40674 — SEC File Number (Identifies the company's filing with the SEC.)
- 52-2210438 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- MaxCyte, Inc. (company) — Registrant
- August 11, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Rockville, Maryland (location) — Principal executive offices
FAQ
Who are the specific directors or officers departing from MaxCyte, Inc.?
The filing does not specify the names of the departing directors or officers, only that such departures are being reported.
Which new officers have been appointed to MaxCyte, Inc.?
The filing indicates the appointment of certain officers but does not list their names or specific roles.
What are the details of the compensatory arrangements for the officers mentioned?
The filing states that compensatory arrangements of certain officers are being reported, but the specific details are not provided in this summary section.
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported is dated August 11, 2025.
What is the principal executive office address for MaxCyte, Inc.?
The principal executive offices are located at 9713 Key West Avenue, Suite 400, Rockville, Maryland 20850.
Filing Stats: 533 words · 2 min read · ~2 pages · Grade level 13.4 · Accepted 2025-08-11 16:30:15
Key Financial Figures
- $0.01 — ge on which registered Common Stock, $0.01 par value MXCT The Nasdaq Stock Mar
Filing Documents
- mxct-20250811x8k.htm (8-K) — 36KB
- 0001558370-25-011056.txt ( ) — 149KB
- mxct-20250811.xsd (EX-101.SCH) — 4KB
- mxct-20250811_lab.xml (EX-101.LAB) — 16KB
- mxct-20250811_pre.xml (EX-101.PRE) — 10KB
- mxct-20250811x8k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MaxCyte, Inc. Dated: August 11, 2025 By: /s/ Douglas Swirsky Douglas Swirsky Chief Financial Officer